Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 2629 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Encorium Q3 net loss widens

Net revenue for the third quarter of 2008 was $7.4 million, an increase of 3.5%, compared to $7.2 million for the third quarter of 2007. The increase in

Ortoviva wins CE approval for distractor system

From a functional perspective, the instruments in the Ortoviva distractor solution hold and separate the two vertebrae adjacent to a damaged disc. This ability to mechanically control position